Skip to main content
Live · TradingView
Back to the NewsWire

Seekingalpha

Published September 12, 2026

Neuronetics a new buy at B Riley on interventional psychiatry platform | Seeking Alpha

ketamine , which has hallucinogenic effects. Spravato's US sales surpassed a $2B run rate in Q1. He noted that the company has replaced executives.

Read the full story at Seekingalpha

Surfaced by this Google Alert

  • Ketamine